Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling

J Transl Med. 2016 May 12;14(1):132. doi: 10.1186/s12967-016-0894-9.

Abstract

Background: Immune regulation is crucial for the pathogenesis of B-cell acute lymphoblastic leukemia (B-ALL). It has been reported that Th17 cells as a newly identified subset of CD4(+) T cells are involved in the pathogenesis of several hematological disorders. However, the role of Th17 cells in the pathophysiology of B-ALL is still unclear.

Methods: The frequencies of T cells were determined by flow cytometry in the peripheral blood and bone marrow of 44 newly diagnosed B-ALL patients and 25 age-matched healthy donors. The cell viability and apoptosis were determined by CCK-8 assay and Annexin V staining, respectively. Western blot was applied to identify the level of Akt and Stat3 phosphorylation.

Results: We assessed and observed a significantly increased frequency of Th17 cells and a drastically decreased frequency of Th1 cells in peripheral blood mononuclear cells and bone marrow mononuclear cells from newly diagnosed B-ALL patients compared with healthy donors. Furthermore, increased levels of Th17-related cytokines including IL-17, IL-21, IL-23, IL-1β, and IL-6 were presented in between blood and marrow in B-ALL patients. Both IL-17A and IL-21, two Th17-secreted cytokines, induced the proliferation of B-ALL cell line Nalm-6 and patient B-ALL cells isolated from B-ALL patients, herein either cytokine led to the phosphorylation of Akt and Stat3. Additionally, IL-17A promoted resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost completely rescued daunorubicin-induced cell death in B-ALL cells.

Conclusions: Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and resistance to daunorubicin in B-ALL cells through activation of Akt signaling. Th17 cells may represent a novel target to improve B-ALL immunotherapy.

Keywords: B-cell acute lymphoblastic leukemia; IL-17A; Th1 cells; Th17 cells.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cell Proliferation / drug effects
  • Cell Separation
  • Daunorubicin / pharmacology*
  • Drug Resistance, Neoplasm / drug effects*
  • Enzyme Activation / drug effects
  • Humans
  • Interleukin-17 / metabolism*
  • Interleukin-21
  • Interleukins / metabolism
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Proto-Oncogene Proteins c-akt / metabolism*
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects*
  • Th1 Cells / immunology
  • Th17 Cells / drug effects
  • Th17 Cells / immunology*
  • Young Adult

Substances

  • IL17A protein, human
  • Interleukin-17
  • Interleukins
  • STAT3 Transcription Factor
  • Proto-Oncogene Proteins c-akt
  • Interleukin-21
  • Daunorubicin